Murphy Michael R buys $38,926,856 stake in Foundation Medicine Inc (FMI)

Foundation Medicine Inc (FMI) : Murphy Michael R scooped up 16,319 additional shares in Foundation Medicine Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 1,574,711 shares of Foundation Medicine Inc which is valued at $38,926,856.Foundation Medicine Inc makes up approximately 13.83% of Murphy Michael R’s portfolio.

Other Hedge Funds, Including , Geode Capital Management boosted its stake in FMI in the latest quarter, The investment management firm added 2,587 additional shares and now holds a total of 102,158 shares of Foundation Medicine Inc which is valued at $2,525,346. Credit Suisse Ag added FMI to its portfolio by purchasing 21,493 company shares during the most recent quarter which is valued at $531,307.Teachers Advisors Inc boosted its stake in FMI in the latest quarter, The investment management firm added 2,434 additional shares and now holds a total of 20,533 shares of Foundation Medicine Inc which is valued at $507,576. Tower Research Capital (trc) sold out all of its stake in FMI during the most recent quarter. The investment firm sold 300 shares of FMI which is valued $7,416. Private Capital Advisors added FMI to its portfolio by purchasing 17,570 company shares during the most recent quarter which is valued at $386,540. Foundation Medicine Inc makes up approx 0.14% of Private Capital Advisors’s portfolio.

Foundation Medicine Inc opened for trading at $20.77 and hit $21.51 on the upside on Monday, eventually ending the session at $21.23, with a gain of 2.36% or 0.49 points. The heightened volatility saw the trading volume jump to 1,46,442 shares. Company has a market cap of $742 M.

On the company’s financial health, Foundation Medicine Inc reported $-0.84 EPS for the quarter, missing the analyst consensus estimate by $ -0.05 based on the information available during the earnings call on Aug 2, 2016. Analyst had a consensus of $-0.79. The company had revenue of $28.24 million for the quarter, compared to analysts expectations of $26.72 million. The company’s revenue was up 25.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.98 EPS.

Foundation Medicine Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. Its platform includes methods and algorithms for analyzing specimens across various types of cancer and for incorporating that information. Its products provide genomic information about each patient’s individual cancer enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its clinical products FoundationOne for solid tumors and FoundationOne Heme for blood-based cancers or hematologic malignancies including leukemia lymphoma myeloma and various sarcomas and pediatric cancers are available comprehensive genomic profiles designed for use in the routine care of patients with cancer. Its brands also include Once. And for All and The Molecular Information Company.

Leave a Reply

Foundation Medicine Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Foundation Medicine Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.